西班牙圣帕布洛大学妊娠期糖尿病研究博士后职位

CEU San Pablo University (CEU) was founded in Madrid in 1993 and it is ranked as the second private university in Spain in research effort. CEU counts with 7 Research Centers, 40 research units and 11 research support services. Currently CEU is developing more than 50 research projects, with a budget that exceeds € 4 million. The University has an increasing history of collaboration with Industry, meaning around 65% of its R&D funding. CEU is looking for a highly motivated candidate to apply for a Marie Skłodowska-Curie Individual Fellowship - Postdoc position. Together with the selected candidate a MSCA IF proposal will be written and submitted. The involvement of the selected candidate in the proposal writing process will provide ample opportunity to tailor the proposal to his / her research interests. A successful application will result in a two-year appointment.
 

Description

CEMBIO – The Center for Metabolomics and Bioanalysis offers an unique opportunity to join selected applicant to participate in currently on-going research project in the emerging field of maternal fetal medicine. Nowadays, strong emphasis on the development of maternal fetal medicine strives to improve maternal, fetal and neonatal outcomes by developing new and improving existing standards of prevention, diagnosis and treatment through application systems biology based research. Our specific interests are centered on the metabolic fingerprinting of Gestational Diabetes Mellitus (GDM). GDM, defined as glucose intolerance with onset or first recognition during pregnancy and approximately is affecting up to 14% of all pregnancies with a rapid growing tendency. However, despite the advances in diagnosis and good maternal diabetic control GDM still has been related to relevant short-term and long-term health complications for mother, fetus or neonate. Furthermore, although diabetes usually remits after pregnancy, women with GDM have a high risk of developing postpartum type 2-diabetes particularly when accompanied by obesity. In addition, women with a history of GDM are also at increased risk of cardiovascular disease. CEMBIO is devoted to innovative, top level research work in the metabolomics field. “Omics” sciences, in particular metabolomics provide deeper insights in the pathogenesis and discovery of biomarker patterns of diseases by obtaining a unique metabolite pattern, or “fingerprint” specific for each sample that provides information of compounds with a potential diagnostic or predictive power. The overriding aim of the GDM project is to discover and validate compounds that could serve as biomarkers for early prediction and diagnosis of metabolic disturbances in pregnancy related to the development of GDM. The secondary aim of the study is to improve knowledge, increase disease understanding and to define new molecular pathophysiological mechanisms related to GDM development. Researcher will be working with a new generation state-of-the-art equipment including liquid chromatography, gas chromatography, and capillary electrophoresis separation platforms coupled with mass spectrometry (LC-QTOF-MS, GC-EI-Q-MS, CE-TOF-MS). Metabolomics data will be incorporated with the clinical characteristics of studied population for comprehensive univariate and multivariate statistical analysis, followed by extensive biochemical interpretation and final data interpretation. Additionally, applicant will have an opportunity to work with international and multidisciplinary group experts, develop research skills and have chance to published results in peer-reviewed high indexes scientific journals. www.metabolomica.uspceu.es.